Highly precise base-editing therapy shows durable VOC-free efficacy and favorable safety in sickle cell disease

▤ Summary

CorrectSequence Therapeutics reported positive 15-month follow-up data for its CS-206 base-editing therapy in a sickle cell disease patient treated in China. The patient remained free of vaso-occlusive crises for more than 15 months and showed favorable safety and efficacy outcomes. The company says its transformer base editor enables precise single-base correction without DNA double-strand breaks, which may reduce key safety risks associated with other gene-editing approaches. CorrectSequence also highlighted its broader clinical pipeline and said global enrollment is underway for the investigator-initiated study of CS-206.

▦ Linked Companies